Dennis Kaysen - Coloplast A/S Director Communications

All Insiders . USA . 
Stock . Coloplast AS . Stakeholders . Insider . Dennis Kaysen
CLPBF Stock  USD 106.00  0.37  0.35%   

Insider

Dennis Kaysen is Director Communications of Coloplast AS
Phone45 49 11 11 11
Webhttps://www.coloplast.com

Coloplast A/S Management Efficiency

The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast A/S's management efficiency ratios could be used to measure how well Coloplast A/S manages its routine affairs as well as how well it operates its assets and liabilities.
Coloplast AS has accumulated 16.36 B in total debt with debt to equity ratio (D/E) of 2.83, implying the company greatly relies on financing operations through barrowing. Coloplast A/S has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Coloplast A/S until it has trouble settling it off, either with new capital or with free cash flow. So, Coloplast A/S's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Coloplast A/S sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Coloplast to invest in growth at high rates of return. When we think about Coloplast A/S's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Martin WiechmannCarl Zeiss Meditec
N/A
Carrie ByingtonBecton Dickinson and
57
Laurie FergusonCarl Zeiss Meditec
N/A
Aurelio SahagunStraumann Holding AG
50
Mike WangCarl Zeiss Meditec
N/A
Steven MDCarl Zeiss Meditec
N/A
Rahma SamowStraumann Holding AG
44
Tomoko NakagawaHoya Corp
N/A
Augustine JDHoya Corp
55
Ariel BauerEssilor International SA
N/A
Andrew ChangCarl Zeiss Meditec
N/A
William BrownBecton Dickinson and
N/A
Marco CatalaniEssilor International SA
N/A
Holger HadererStraumann Holding AG
54
Giorgio IannellaEssilor International SA
N/A
Antoine EzellBecton Dickinson and
51
Taishi ArashidaHoya Corp
N/A
Euan ThomsonCarl Zeiss Meditec
60
FACC MDBecton Dickinson and
N/A
Steven MDCarl Zeiss Meditec
N/A
KokKien LohStraumann Holding AG
56
Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast is traded on OTC Exchange in the United States. Coloplast AS [CLPBF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.75
Return On Asset0.17

Coloplast A/S Leadership Team

Elected by the shareholders, the Coloplast A/S's board of directors comprises two types of representatives: Coloplast A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coloplast. The board's role is to monitor Coloplast A/S's management team and ensure that shareholders' interests are well served. Coloplast A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coloplast A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ellen Bjurgert, VP Relations
Allan Rasmussen, Executive VP of Global Operations
Alain Morvan, Senior Vice President Sales Europe
Thomas Barfod, Director, Employee Representative
Nicolai Andersen, Senior Vice President Wound Care
Anders LonningSkovgaard, CFO, Executive Vice President Member of the Executive Management
Kristian Villumsen, Executive VP of Chronic Care
Paul Marcun, Senior Vice President Emerging Markets
Dorthe Ronnau, VP Culture
Dennis Kaysen, Director Communications

Coloplast Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Coloplast A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.75
Return On Asset0.17
Profit Margin0.20 %
Operating Margin0.30 %
Current Valuation28.84 B
Shares Outstanding194.31 M
Shares Owned By Insiders35.00 %
Shares Owned By Institutions25.53 %
Price To Earning37.47 X
Price To Book22.60 X

Currently Active Assets on Macroaxis

VVisa Class A
SSentinelOne
GMGeneral Motors
MSFTMicrosoft
FFord Motor

Other Information on Investing in Coloplast Pink Sheet

Coloplast A/S financial ratios help investors to determine whether Coloplast Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast A/S security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY